Aytu BioPharma (NASDAQ:AYTU) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Aytu BioPharma (NASDAQ:AYTU) from a hold rating to a strong sell rating in a report published on Tuesday,Zacks.com reports.

AYTU has been the topic of several other research reports. Wall Street Zen upgraded Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th. Ascendiant Capital Markets boosted their target price on shares of Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a report on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $9.33.

Aytu BioPharma Stock Performance

Shares of AYTU stock opened at $2.68 on Tuesday. The stock has a market cap of $28.76 million, a PE ratio of -0.70 and a beta of 0.27. The business has a 50-day simple moving average of $2.51 and a 200-day simple moving average of $2.38. The company has a quick ratio of 1.03, a current ratio of 1.16 and a debt-to-equity ratio of 0.70. Aytu BioPharma has a 52-week low of $0.95 and a 52-week high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last posted its earnings results on Tuesday, February 3rd. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.79). The company had revenue of $15.17 million for the quarter, compared to analyst estimates of $12.17 million. Aytu BioPharma had a negative return on equity of 28.22% and a negative net margin of 39.02%.

Institutional Trading of Aytu BioPharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Stonepine Capital Management LLC raised its position in shares of Aytu BioPharma by 75.3% during the 2nd quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock worth $1,772,000 after purchasing an additional 348,955 shares during the last quarter. AWM Investment Company Inc. acquired a new stake in Aytu BioPharma in the 2nd quarter worth about $1,351,000. Diadema Partners LP boosted its holdings in Aytu BioPharma by 12.1% in the 4th quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock worth $795,000 after buying an additional 33,118 shares during the last quarter. Persistent Asset Partners Ltd increased its stake in Aytu BioPharma by 27.2% during the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after buying an additional 16,963 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in Aytu BioPharma by 96.2% during the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after buying an additional 33,701 shares in the last quarter. Hedge funds and other institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.